Amanda Chantziou

Ms. Amanda Chantziou

Laboratory of Biochemistry, School of Medicine, University of Crete, Greece

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
HPHara Polioudaki
Hara Polioudaki
ACAmanda Chantziou
Amanda Chantziou
KKKonstantina Kalyvianaki
Konstantina Kalyvianaki
PMPanagiotis Malamos
Panagiotis Malamos
George NotasGeorge Notas
George Notas
Panayiotis TheodoropoulosPanayiotis Theodoropoulos
Panayiotis Theodoropoulos

11 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HPHara Polioudaki
Hara Polioudaki
AMAnastasia Mala
Anastasia Mala
EGEleni Gkimprixi
Eleni Gkimprixi
Maria A PapadakiMaria A Papadaki
Maria A Papadaki
ACAmanda Chantziou
Amanda Chantziou
Panayiotis TheodoropoulosPanayiotis Theodoropoulos
Panayiotis Theodoropoulos
We aimed to evaluate the co-expression of PD-L1 and epithelial-mesenchymal markers in CTCs from metastatic breast cancer (MBC) patients and to determine if there is any relationship with patients’ outcome after eribulin treatment. Using cytospin preparations of peripheral blood mononuclear cells (PBMCs) from MBC patients treated with eribulin and a combination of immunocytochemistry and immunofluorescence, we quantified PD-L1, keratins and vimentin in single and cluster CTCs on days 1 and 8 of the first-treatment cycle. CTCs (n = 173) were found in 31 out of 38 patients. At baseline, the presence of cluster CTCs (p = 0.048), cluster mesenchymal CTCs (mCTCs) (p = 0.0003) or cluster PD-L1+mCTCs (p = 0.006) was associated with shorter overall survival (OS). In multivariate cox regression analysis, the detection of cluster mCTCs was the only parameter associated with increased risk of death (p = 0.024). On day 8 post-eribulin administration, PD-L1+mCTCs and especially single PD-L1+mCTCs decreased in 75% and 89% of patients, respectively. The detection of single PD-L1+mCTCs after eribulin treatment was correlated with shorter PFS (p = 0.047) and OS (p = 0.020). In conclusion, our study identified for the first time that cluster and single PD-L1+mCTCs subpopulations are of clinical significance in patients with MBC and highlighted the importance of CTC phenotyping during treatment with eribulin.

Verified
Journal Article
Open access
PDF file
ACAmanda Chantziou
Amanda Chantziou
KTKostas Theodorakis
Kostas Theodorakis
HPHara Polioudaki
Hara Polioudaki
Eelco De BreeEelco De Bree
Eelco De Bree
Marilena KampaMarilena Kampa
Marilena Kampa
Panayiotis TheodoropoulosPanayiotis Theodoropoulos
Panayiotis Theodoropoulos
In breast cancer, expression of Cluster of Differentiation 24 (CD24), a small GPI-anchored glycoprotein at the cell periphery, is associated with metastasis and immune escape, while its absence is associated with tumor-initiating capacity. Since the mechanism of CD24 sorting is unknown, we investigated the role of glycosylation in the subcellular localization of CD24. Expression and localization of wild type N36- and/or N52-mutated CD24 were analyzed using immunofluorescence in luminal (MCF-7) and basal B (MDA-MB-231 and Hs578T) breast cancer cells lines, as well as HEK293T cells. Endogenous and exogenously expressed wild type and mutated CD24 were found localized at the plasma membrane and the cytoplasm, but not the nucleoplasm. The cell lines showed different kinetics for the sorting of CD24 through the secretory/endocytic pathway. N-glycosylation, especially at N52, and its processing in the Golgi were critical for the sorting and expression of CD24 at the plasma membrane of HEK293T and basal B type cells, but not of MCF-7 cells. In conclusion, our study highlights the contribution of N-glycosylation for the subcellular localization of CD24. Aberrant N-glycosylation at N52 of CD24 could account for the lack of CD24 expression at the cell surface of basal B breast cancer cells.